Department of Ophthalmology, The Ohio State University Wexner Medical Center, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USA.
Department of Ophthalmology, The University of Arizona Medical Center, 655 North Alvernon Way, Suite 108, Tucson, AZ 85711, USA.
Mediators Inflamm. 2013;2013:515312. doi: 10.1155/2013/515312. Epub 2013 Nov 20.
Vitreous inflammation, or vitritis, may result from many causes, including both infectious and noninfectious, including rheumatologic and autoimmune processes. Vitritis is commonly vision threatening and has serious sequelae. Treatment is frequently challenging, but, today, there are multiple methods of systemic treatment for vitritis. These categories include corticosteroids, antimetabolites, alkylating agents, T-cell inhibitors/calcineurin inhibitors, and biologic agents. These treatment categories were reviewed last year, but, even over the course of just a year, many therapies have made progress, as we have learned more about their indications and efficacy. We discuss here discoveries made over the past year on both existing and new drugs, as well as reviewing mechanisms of action, clinical dosages, specific conditions that are treated, adverse effects, and usual course of treatment for each class of therapy.
玻璃体炎症,或玻璃体炎,可能由多种原因引起,包括感染性和非感染性原因,包括风湿性和自身免疫性疾病。玻璃体炎通常会威胁视力,并产生严重的后果。治疗通常具有挑战性,但如今,有多种治疗玻璃体炎的全身治疗方法。这些类别包括皮质类固醇、抗代谢物、烷化剂、T 细胞抑制剂/钙调神经磷酸酶抑制剂和生物制剂。去年我们对这些治疗类别进行了回顾,但即使在仅仅一年的时间里,随着我们对它们的适应症和疗效有了更多的了解,许多疗法也取得了进展。我们在这里讨论了过去一年在现有和新药物方面的发现,以及回顾作用机制、临床剂量、治疗的具体情况、不良反应以及每种治疗类别的常规治疗过程。